• 1
    Royal Decree of 21 December 2001 (published 29 December 2001): Koninklijk besluit van 21 december 2001 tot vaststelling van de procedures, termijnen en voorwaarden inzake de tegemoetkoming van de verplichte verzekering voor geneeskundige verzorging en uitkeringen in de kosten van farmaceutische specialiteiten, B.S. 29 december 2001 // Arrêté royal de 21 décembre 2001 fixant les procédures, délais et conditions concernant l'intervention de l'assurance obligatoire soins de santé et indemnités dans le coût des spécialités pharmaceutiques, M.B. le 29 décembre 2001, 2001.
  • 2
    Van Wilder P, Dupont A. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 2007;2007:5244733.
  • 3
    Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003;9:5361.
  • 4
    College voor Zorgverzekeringen (CVZ). Guidelines for Pharmacoeconomic Research, updated version. Diemen: CVZ, 2006.
  • 5
    Collège des économists de la santé (CES). French Guidelines for the Economic Evaluation of Health Care Technologies. Paris: CES, 2004.
  • 6
    Australian Department of Health and Aging. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.2). Pharmaceutical Benefits Advisory Committee, 2007.
  • 7
    National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. Draft for Consultation. London: NICE, 2007.
  • 8
    Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for Pharmacoeconomic Evaluations in Belgium. KCE Reports. Bruxelles: Belgian Health Care Knowledge Centre (KCE), 2008.
  • 9
    Khan KS, Ter Riet G, Glanville J, et al. Undertaking Systematic Reviews of Research on Effectiveness. CRD's Guidance for those Carying Out of Commissioning Reviews. York: NHS Centre for Reviews and Dissemination, University of York, 2001.
  • 10
    Mays N, Pope C. Qualitative Research in Health Care. London: BMJ Publishing Group, 1996.
  • 11
    Verhagen AP, De Vet HC, De Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:123541.
  • 12
    Popay J, Rogers A, Williams G. Rationale and standards for the systematic review of qualitative literature in health services research. Qual Health Res 1998;8:34151.
  • 13
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:27583.
  • 14
    Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365: 8293.
  • 15
    Drummond M, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford, Melbourne, New York: Oxford University Press, 1997.
  • 16
    Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326:472.
  • 17
    Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:68391.
  • 18
    Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26):1152.
  • 19
    Van De Sande S, De Wachter D, Swartenbroekx N, et al. Inventaris van databanken gezondheidszorg. KCE Reports. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2006.
  • 20
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003;6:917.
  • 21
    Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005;43:514.
  • 22
    Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3.
  • 23
    Gravelle H, Smith D. Discounting for health effects in cost–benefit and cost-effectiveness analysis. Health Econ 2001;10:58799.
  • 24
    Brouwer WB, Van Exel NJ. Discounting in decision making: the consistency argument revisited empirically. Health Policy 2004; 67:18794.
  • 25
    Claxton K, Sculpher M, Culyer A, et al. Discounting and cost-effectiveness in NICE—stepping back to sort out a confusion. Health Econ 2006;15:14.
  • 26
    Brouwer W, Van Hout B, Rutten F. A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 2000;5:1148.
  • 27
    Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009 in press.